Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:MNKDNASDAQ:NVAXNASDAQ:RIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$19.53-0.7%$18.89$14.40▼$47.00$1.30B1.33918,096 shs667,715 shsMNKDMannKind$4.30-1.1%$4.58$4.05▼$7.63$1.31B1.142.37 million shs1.13 million shsNVAXNovavax$6.99-2.2%$6.58$5.01▼$23.86$1.13B3.216.89 million shs5.55 million shsRIGLRigel Pharmaceuticals$20.97+2.1%$18.52$7.48▼$29.82$374.78M1.34219,039 shs159,778 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-0.71%-1.56%+6.14%-5.52%-40.84%MNKDMannKind-1.15%+4.37%-10.04%-13.65%-9.09%NVAXNovavax-2.24%-2.78%+15.16%-16.19%-66.67%RIGLRigel Pharmaceuticals+2.09%+7.37%+14.84%+2.19%+114.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.7681 of 5 stars4.50.00.00.02.70.00.0MNKDMannKind2.9427 of 5 stars3.61.00.00.02.91.71.9NVAXNovavax3.5654 of 5 stars3.21.00.04.72.40.80.6RIGLRigel Pharmaceuticals2.9037 of 5 stars3.21.00.00.04.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.90Moderate Buy$53.90175.99% UpsideMNKDMannKind 3.25Buy$10.00132.56% UpsideNVAXNovavax 2.43Hold$19.00171.82% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4073.58% UpsideCurrent Analyst Ratings BreakdownLatest RIGL, CLDX, MNKD, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/20/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$46.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.56M171.51N/AN/A$9.08 per share2.15MNKDMannKind$297.60M4.39N/AN/A($0.91) per share-4.73NVAXNovavax$1.21B0.93N/AN/A($6.04) per share-1.16RIGLRigel Pharmaceuticals$203.08M1.85N/AN/A($1.64) per share-12.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%8/14/2025 (Estimated)MNKDMannKind-$11.94M$0.1061.4318.70N/A8.07%-17.74%8.68%8/6/2025 (Estimated)NVAXNovavax-$545.06M$2.65N/A87.382.85-32.18%N/A-17.05%8/14/2025 (Estimated)RIGLRigel Pharmaceuticals-$25.09M$2.07149.8019.97N/A2.46%-14.80%3.03%8/5/2025 (Estimated)Latest RIGL, CLDX, MNKD, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27MNKDMannKindN/A4.544.17NVAXNovavaxN/A0.930.93RIGLRigel PharmaceuticalsN/A1.961.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AMNKDMannKind49.55%NVAXNovavax53.04%RIGLRigel Pharmaceuticals66.23%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%MNKDMannKind2.70%NVAXNovavax1.00%RIGLRigel Pharmaceuticals9.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableMNKDMannKind400303.93 million267.51 millionOptionableNVAXNovavax1,990161.97 million158.58 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.02 millionOptionableRIGL, CLDX, MNKD, and NVAX HeadlinesRecent News About These CompaniesMillennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 5 at 3:42 AM | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.40 Consensus PT from BrokeragesJune 5 at 1:17 AM | americanbankingnews.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $676,000 in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 4 at 4:13 AM | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Hold" from BrokeragesJune 2, 2025 | marketbeat.comSquarepoint Ops LLC Purchases 18,159 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 1, 2025 | marketbeat.comTwo Sigma Advisers LP Grows Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)June 1, 2025 | marketbeat.comIs Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now?May 29, 2025 | zacks.comWall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High?May 28, 2025 | zacks.comRigel to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comJane Street Group LLC Has $1.05 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 24, 2025 | marketbeat.comRigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 CongressMay 22, 2025 | prnewswire.comSoleus Capital Management L.P. Boosts Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 21, 2025 | marketbeat.com17,123 Shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Acquired by Dimensional Fund Advisors LPMay 20, 2025 | marketbeat.comEnsign Peak Advisors Inc Makes New $1.44 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 19, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)May 17, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 16, 2025 | marketbeat.comHere's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock NowMay 14, 2025 | zacks.comIs Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now?May 13, 2025 | zacks.comUpgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) ForecastsMay 11, 2025 | finance.yahoo.comB. Riley Expects Reduced Earnings for Rigel PharmaceuticalsMay 11, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of RIGL Q2 EarningsMay 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRIGL, CLDX, MNKD, and NVAX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$19.53 -0.14 (-0.71%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$19.52 -0.01 (-0.05%) As of 06/5/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.MannKind NASDAQ:MNKD$4.30 -0.05 (-1.15%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$4.28 -0.02 (-0.56%) As of 06/5/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Novavax NASDAQ:NVAX$6.99 -0.16 (-2.24%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$6.98 -0.02 (-0.21%) As of 06/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Rigel Pharmaceuticals NASDAQ:RIGL$20.97 +0.43 (+2.09%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$20.80 -0.16 (-0.79%) As of 06/5/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
